Drug intelligence / Profile preview

NAI001

Development stage: Preclinical
Lead developer: Hangzhou Nain Biotechnology
Modality: Small Molecules

Overview

NAI001 is a preclinical small molecule inhibitor developed by Hangzhou Nain Biotechnology that targets the transcription factor OCT4 (also known as POU domain, class 5, transcription factor 1 or POU5F1). OCT4 is a master regulator of pluripotency and self-renewal in embryonic stem cells and is frequently overexpressed in cancer stem cells (CSCs), where it drives tumor progression, metastasis, and resistance to conventional therapies. By specifically inhibiting OCT4, NAI001 is designed to deplete the cancer stem cell population and sensitize solid tumors to treatment, potentially offering a novel therapeutic approach for advanced malignancies.

Targets

POU5F1 (Octamer-binding transcription factor 4)

Beyond the preview

Go deeper on NAI001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAI001.

Explore the full profile